Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREMIER: Intensive Lipid Elimination in ACS
NCT02347098Phase 3Completed
- Sponsor
- VA Office of Research & Development
- Start
- Mar 2015
- Primary completion
- Feb 2018
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by VA Office of Research & Development. Primary endpoint: Change in the Total Atheroma Volume From Baseline to 12 Weeks. Started Mar 2015; status: completed.
Beyond the preview
Go deeper on NCT02347098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02347098.